• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Choice of commercially available CAR-T cell products for r/r DLBCL & PMBCL in Europe: a survey on behalf of the cellular therapy & immunobiology working party (CTIWP) of the EBMT.

作者信息

Novak Urban, Mooyaart Jarl E, Daskalakis Michael, Scheid Christof, Gabellier Ludovic, Yakoub-Agha Ibrahim, Ram Ron, Forcade Edouard, López-Corral Lucía, Nicholson Emma, Galli Eugenio, Stölzel Friedrich, Bethge Wolfgang, Wagner-Drouet Eva Maria, Hoogenboom Jorinde D, Mielke Stephan, Arber Caroline, Simonetta Federico, Chabannon Christian, Kuball Jürgen, Ruggeri Annalisa, Malard Florent

机构信息

Department of Medical Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

EBMT Statistical Unit, Leiden, The Netherlands.

出版信息

Bone Marrow Transplant. 2024 Nov;59(11):1631-1634. doi: 10.1038/s41409-024-02401-4. Epub 2024 Aug 27.

DOI:10.1038/s41409-024-02401-4
PMID:39192081
Abstract
摘要

相似文献

1
Choice of commercially available CAR-T cell products for r/r DLBCL & PMBCL in Europe: a survey on behalf of the cellular therapy & immunobiology working party (CTIWP) of the EBMT.欧洲复发/难治性弥漫性大B细胞淋巴瘤和原发性纵隔大B细胞淋巴瘤商用CAR-T细胞产品的选择：代表欧洲血液与骨髓移植协会细胞治疗与免疫生物学工作组（CTIWP）开展的一项调查
Bone Marrow Transplant. 2024 Nov;59(11):1631-1634. doi: 10.1038/s41409-024-02401-4. Epub 2024 Aug 27.
2
Severe ICANS after CAR T-cell therapy and assessment of prevention with levetiracetam for seizure prophylaxis following CAR T-cell for DLBCL & PMBCL in Europe: a survey on behalf of the Cellular Therapy & Immunobiology Working Party (CTIWP) of the EBMT.欧洲CAR T细胞治疗后严重免疫效应细胞相关神经毒性综合征（ICANS）及左乙拉西坦预防弥漫性大B细胞淋巴瘤（DLBCL）和原发性纵隔大B细胞淋巴瘤（PMBCL）患者CAR T细胞治疗后癫痫发作的评估：代表欧洲血液和骨髓移植协会（EBMT）细胞治疗与免疫生物学工作组（CTIWP）开展的一项调查
Bone Marrow Transplant. 2025 Jan;60(1):100-102. doi: 10.1038/s41409-024-02451-8. Epub 2024 Oct 25.
3
Handling, processing and disposal of stem cell products in Europe: A survey by the cellular therapy and immunobiology working party of the European Society for Blood and Marrow Transplantation.欧洲间充质干细胞产品的处理、加工和处置：欧洲血液和骨髓移植学会细胞治疗和免疫生物学工作组的调查。
Cytotherapy. 2018 Mar;20(3):453-460. doi: 10.1016/j.jcyt.2017.12.005. Epub 2018 Jan 17.
4
The European Society for Blood and Marrow Transplantation (EBMT) roadmap and perspectives to improve nutritional care in patients undergoing hematopoietic stem cell transplantation on behalf of the Cellular Therapy and Immunobiology Working Party (CTIWP) and the Nurses Group (NG) of the EBMT.欧洲血液和骨髓移植学会（EBMT）改善造血干细胞移植患者营养护理的路线图和展望，代表细胞治疗和免疫生物学工作组（CTIWP）和 EBMT 的护士组（NG）。
Bone Marrow Transplant. 2023 Sep;58(9):965-972. doi: 10.1038/s41409-023-02018-z. Epub 2023 Jul 5.
5
Diagnosis and Management of Secondary HLH/MAS Following HSCT and CAR-T Cell Therapy in Adults; A Review of the Literature and a Survey of Practice Within EBMT Centres on Behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP).成人造血干细胞移植和嵌合抗原受体T细胞疗法后继发性噬血细胞性淋巴组织细胞增生症/巨噬细胞活化综合征的诊断与管理；文献综述及代表自身免疫性疾病工作组（ADWP）和移植并发症工作组（TCWP）对欧洲血液和骨髓移植协会（EBMT）中心的实践调查
Front Immunol. 2020 Mar 31;11:524. doi: 10.3389/fimmu.2020.00524. eCollection 2020.
6
Defining the impact of SARS-COV-2 on delivery of CAR T-cell therapy in Europe: a retrospective survey from the CTIWP of the EBMT.确定SARS-CoV-2对欧洲嵌合抗原受体T细胞疗法（CAR T细胞疗法）实施的影响：来自欧洲血液与骨髓移植协会细胞治疗工作小组（EBMT-CTIWP）的一项回顾性调查
Bone Marrow Transplant. 2022 Feb;57(2):299-301. doi: 10.1038/s41409-021-01483-8. Epub 2021 Nov 20.
7
Fresh or frozen grafts for allogeneic stem cell transplantation: conceptual considerations and a survey on the practice during the COVID-19 pandemic from the EBMT Infectious Diseases Working Party (IDWP) and Cellular Therapy & Immunobiology Working Party (CTIWP).新鲜或冷冻移植物用于异基因造血干细胞移植：来自 EBMT 传染病工作组 (IDWP) 和细胞治疗与免疫生物学工作组 (CTIWP) 在 COVID-19 大流行期间的概念性考虑和实践调查。
Bone Marrow Transplant. 2023 Dec;58(12):1348-1356. doi: 10.1038/s41409-023-02099-w. Epub 2023 Sep 6.
8
Current use of fecal microbiota transfer in patients with hematologic diseases: a survey on behalf of the Cellular Therapy and Immunobiology Working Party of the EBMT.血液系统疾病患者粪便微生物群移植的当前应用：欧洲血液与骨髓移植协会细胞治疗与免疫生物学工作组的一项调查
Bone Marrow Transplant. 2023 Dec;58(12):1419-1421. doi: 10.1038/s41409-023-02115-z. Epub 2023 Oct 3.
9
Natural killer cell alloreactivity in HLA-haploidentical hematopoietic transplantation: a study on behalf of the CTIWP of the EBMT.自然杀伤细胞同种异体反应性在 HLA 单倍体相合造血移植中的研究：代表 EBMT 的 CTIWP 的研究。
Bone Marrow Transplant. 2021 Aug;56(8):1900-1907. doi: 10.1038/s41409-021-01259-0. Epub 2021 Mar 25.
10
Correction: Donor lymphocyte infusions after haploidentical stem cell transplantation with PTCY: A study on behalf of the EBMT cellular therapy & immunobiology working party.更正：单倍体相合干细胞移植联合PTCY后供体淋巴细胞输注：一项代表欧洲血液与骨髓移植协会细胞治疗与免疫生物学工作组开展的研究
Bone Marrow Transplant. 2023 Jan;58(1):119-120. doi: 10.1038/s41409-022-01855-8.

引用本文的文献

1
Tonic signaling in CAR-T therapy: the lever long enough to move the planet.嵌合抗原受体T细胞（CAR-T）疗法中的张力信号传导：撬动地球的足够长杠杆。
Front Med. 2025 Mar 21. doi: 10.1007/s11684-025-1130-x.

本文引用的文献

1
Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients.原发中枢神经系统淋巴瘤和继发中枢神经系统淋巴瘤中嵌合抗原受体 T 细胞治疗的毒性和疗效：128 例患者的荟萃分析。
Blood Adv. 2023 Jan 10;7(1):32-39. doi: 10.1182/bloodadvances.2022008525.
2
A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma.Tisagenlecleucel 和 axicabtagene ciloleucel CAR T 细胞治疗复发或难治性弥漫性大 B 细胞淋巴瘤的真实世界比较。
Nat Med. 2022 Oct;28(10):2145-2154. doi: 10.1038/s41591-022-01969-y. Epub 2022 Sep 22.
3
GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany.
德国 GLA/DRST 真实世界研究分析嵌合抗原受体 T 细胞疗法治疗大 B 细胞淋巴瘤的结果。
Blood. 2022 Jul 28;140(4):349-358. doi: 10.1182/blood.2021015209.
4
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.阿基仑赛注射液二线治疗大 B 细胞淋巴瘤。
N Engl J Med. 2022 Feb 17;386(7):640-654. doi: 10.1056/NEJMoa2116133. Epub 2021 Dec 11.
5
Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma.利妥昔单抗细胞与 axi-cel 在复发或难治性大 B 细胞淋巴瘤中的匹配调整间接治疗比较。
J Hematol Oncol. 2021 Sep 8;14(1):140. doi: 10.1186/s13045-021-01144-9.
6
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.Tisagenlecleucel 治疗成人复发或难治性弥漫性大 B 细胞淋巴瘤。
N Engl J Med. 2019 Jan 3;380(1):45-56. doi: 10.1056/NEJMoa1804980. Epub 2018 Dec 1.
7
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.阿基仑赛注射液嵌合抗原受体T细胞疗法治疗难治性大B细胞淋巴瘤
N Engl J Med. 2017 Dec 28;377(26):2531-2544. doi: 10.1056/NEJMoa1707447. Epub 2017 Dec 10.